GlaxoSmithkline Pharmaceuticals Ltd (GLAX)

Currency in INR
2,643.90
-43.20(-1.61%)
Real-time Data·
GLAX Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
GLAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,621.102,687.00
52 wk Range
1,921.003,515.70
Key Statistics
Bid/Ask
2,643.80 / 2,644.00
Prev. Close
2,687.1
Open
2,678
Day's Range
2,621.1-2,687
52 wk Range
1,921-3,515.7
Volume
46.45K
Average Volume (3m)
164.34K
1-Year Change
-6.11%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

GlaxoSmithkline Pharmaceuticals Ltd Company Profile

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.

Employees
3113
Market
India

Compare GLAX to Peers and Sector

Metrics to compare
GLAX
Peers
Sector
Relationship
P/E Ratio
47.9x32.3x−0.5x
PEG Ratio
0.991.300.00
Price/Book
23.3x5.2x2.6x
Price / LTM Sales
12.2x5.2x3.3x
Upside (Analyst Target)
16.8%11.6%42.9%
Fair Value Upside
Unlock−0.6%6.2%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 56.10%
Dividend Yield
1.56%
Industry Median 0.74%
Annualised payout
42.00
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Aug 01, 2025
EPS / Forecast
12.10 / --
Revenue / Forecast
8.05B / 8.84B
EPS Revisions
Last 90 days

GLAX Income Statement

People Also Watch

14,600.00
SLIN
-1.95%
5,493.00
HDFA
-0.15%
271.80
ADTB
+0.22%
355.65
BION
+3.96%
811.65
NIPF
+0.71%

FAQ

What Stock Exchange Does GlaxoSmithkline Pharma Trade On?

GlaxoSmithkline Pharma is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for GlaxoSmithkline Pharma?

The stock symbol for GlaxoSmithkline Pharma is "GLAX."

What Is the GlaxoSmithkline Pharma Market Cap?

As of today, GlaxoSmithkline Pharma market cap is 447.50B.

What Is GlaxoSmithkline Pharma's Earnings Per Share (TTM)?

The GlaxoSmithkline Pharma EPS (TTM) is 56.10.

When Is the Next GlaxoSmithkline Pharma Earnings Date?

GlaxoSmithkline Pharma will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is GLAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GlaxoSmithkline Pharma Stock Split?

GlaxoSmithkline Pharma has split 1 times.

How Many Employees Does GlaxoSmithkline Pharma Have?

GlaxoSmithkline Pharma has 3113 employees.

What is the current trading status of GlaxoSmithkline Pharma (GLAX)?

As of 12 Aug 2025, GlaxoSmithkline Pharma (GLAX) is trading at a price of 2,643.90, with a previous close of 2,687.10. The stock has fluctuated within a day range of 2,621.10 to 2,687.00, while its 52-week range spans from 1,921.00 to 3,515.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.